IGEN gets $505 million damages and exit from Roche deal
This article was originally published in Clinica
Tiny US company IGEN international has won a highly significant victory in the courts against Swiss giant Roche Diagnostics. Roche has been ordered to pay IGEN $505 million in damages in the companies' long-running dispute over the licensing of IGEN's Origen electrochemiluminescence (ECL) technology to Roche. It also allows IGEN to end its licence agreement with Roche.